Compare · CLOV vs ILMN
CLOV vs ILMN
Side-by-side comparison of Clover Health Investments Corp. (CLOV) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLOV and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $40.46B, about 16.3x CLOV ($2.49B).
- Over the past year, CLOV is up 66.4% and ILMN is up 173.7% - ILMN leads by 107.3 points.
- CLOV has been more active in the news (15 items in the past 4 weeks vs 8 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 13 for CLOV).
- Company
- Clover Health Investments Corp.
- Illumina Inc.
- Price
- $4.49-4.27%
- $262.52-2.06%
- Market cap
- $2.49B
- $40.46B
- 1M return
- -0.99%
- +7.01%
- 1Y return
- +66.42%
- +173.74%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 15
- 8
- Recent ratings
- 13
- 25
Clover Health Investments Corp.
Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CLOV
- SEC Form 8-K filed by Clover Health Investments Corp.
- Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027
- SEC Form 4 filed by Clover Health Investments Corp.
- Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
- SEC Form 4 filed by Clover Health Investments Corp.
- Director Miller Brian James was granted 12,481 shares (SEC Form 4)
- Director Torricelli Robert G was granted 12,481 shares, increasing direct ownership by 7% to 186,897 units (SEC Form 4)
- Chief Executive Officer Toy Andrew sold $1,335,797 worth of shares (318,806 units at $4.19), decreasing direct ownership by 3% to 9,140,510 units (SEC Form 4) to cover taxes
- New insider Torricelli Robert G claimed ownership of 174,416 shares (SEC Form 3)
- SEC Form 3 filed by new insider Miller Brian James
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)